Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

“We are aiming for the fall of this year, and the writers’ room is working so hard now,” Sanada told Variety Saturday at AARP’s Movies for Grownups Awards in Los Angeles. “We’re going ...

A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. Fellow Japanese drugmaker Ono Pharmaceutical has won an FDA green light for vimseltinib to treat ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Japan's health ministry said on Friday it agreed to buy 1.4 million doses of Daiichi Sankyo's updated COVID-19 vaccine. The purchase is contingent on approval of the shot formulated for the XBB.1. ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...